Table 3.
Demographics and clinical characteristics of HEDS cohort at baseline.
| HEDS (n = 1482) | |
|---|---|
| Male, n (%) | 808 (54.5%) |
| BMI (kg/m2) | |
| Median (25th percentile, 75th percentile) | 30.7 (26.9, 36.0) |
| Min, max | 7.6, 87.1 |
| Race, n (%) | |
| White or Caucasian | 1250 (84.3%) |
| Black or African-American | 98 (6.6%) |
| Asian | 32 (2.2%) |
| Other | 102 (6.9%) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 159 (10.7%) |
| Age (y) | |
| Median (25th percentile, 75th percentile) | 60 (54, 65) |
| Min, max | 18, 87 |
| Etiology of liver disease | |
| History of HCV infection, n (%) | 439 (29.6%) |
| SVR achieved | 97 (22.1%) |
| HBV infection, n (%) | 27 (1.8%) |
| NASH | 279 (18.8%) |
| Alcoholic hepatitis | 313 (21.1%) |
| Autoimmune hepatitis | 80 (5.4%) |
| Cholestatic liver disease (PBC, PSC) | 112 (7.6%) |
| Other | 109 (7.4%) |
| Child-Turcotte-Pugh Class A, n (%) | 1048 (70.7%) |
| Alcohol use, n current (%) | 941 (63.5%) |
| Tobacco use, n (%) | |
| Current | 217 (14.6%) |
| Former | 834 (56.3%) |
| Fully active performance status, n (%) | 979 (66.1%) |
| Medications of interest, n ever taken (%) | |
| DAA therapy for HCV | 134 (9.0%) |
| Statins | 344 (23.2%) |
| Metformin | 112 (7.6%) |
| Interferon therapy | 28 (1.9%) |
| Non-DAA antiviral agents | 292 (19.7) |
| Coffee and tea consumption, n (%) | 854 (57.6%) |
| Obesity, n (%) | 804 (54.2%) |
| Cancer history (excl. liver), n (%) | 98 (6.6%) |
| Family cancer history, n (%) | |
| Liver cancer | 65 (4.3%) |
| Other cancer | 706 (47.6%) |
| Family liver disease history, n (%) | 291 (19.6%) |
Cohort data are inclusive of DCP-V subjects who have continued in follow-up through the HEDS study.